Blueprint Medicines

Avapritinib (AYVAKYT) is an oral small-molecule stem cell growth factor receptor inhibitor targeting platelet-derived growth factor receptor alpha (PDGFRA), developed by Blueprint Medicines (Netherlands) B.V. for the treatment of gastrointestinal stromal tumors (GIST). The drug represents a targeted approach to GIST management, a rare malignancy driven by PDGFRA mutations. Avapritinib has completed Phase 3 development as of October 2022, with the program identified by internal code BLU-285-1303. The compound has achieved regulatory approval in both the United States and European Union, with EU authorization granted on 27 November 2025 under the brand name AYVAKYT (EMA product number EMEA/H/C/005208). The US approval was secured under NDA 212608. Blueprint Medicines' strategy centers on precision oncology targeting rare tumor subtypes with defined molecular drivers. The completion of Phase 3 trials and subsequent regulatory approvals reflect the clinical validation of avapritinib's efficacy and safety profile in GIST populations. The drug's approval in major markets positions it within the competitive landscape of GIST therapeutics, though the specific clinical trial endpoints and comparative efficacy data remain to be detailed in regulatory documentation.

Gastrointestinal stromal tumors (GIST) represent a rare but significant oncologic indication with limited treatment options historically. GIST is characterized by activating mutations in KIT or PDGFRA genes, with PDGFRA-mutant GIST representing a distinct molecular subset. The approval of avapritinib addresses an unmet medical need in PDGFRA-driven GIST, particularly in patients with specific mutations such as PDGFRA D842V, which confers resistance to conventional tyrosine kinase inhibitors. The rarity of GIST (approximately 3,000–6,000 new cases annually in the US) creates a focused but commercially significant niche market. Avapritinib's oral bioavailability and targeted mechanism offer potential advantages in tolerability and efficacy compared to broad-spectrum kinase inhibitors. The competitive landscape includes multiple tyrosine kinase inhibitors and multimodal oncology agents, though few are specifically optimized for PDGFRA-mutant GIST. Market relevance is driven by the precision medicine paradigm, where molecular profiling increasingly determines therapeutic selection. The patient population for PDGFRA-mutant GIST is smaller than the overall GIST population but represents a high-value segment due to unmet medical need and the specificity of molecular targeting. Commercial significance is enhanced by orphan drug designation potential and the rarity-driven pricing environment for targeted oncology therapeutics.

Drug Class: Targeted oncology agent; small-molecule tyrosine kinase inhibitor.

Mechanism of Action: Stem cell growth factor receptor inhibitor; specifically targets platelet-derived growth factor receptor alpha (PDGFRA).

Molecular Modality: Small-molecule oral formulation.

Route of Administration: Oral.

Primary Target: Platelet-derived growth factor receptor alpha (PDGFRA).

Therapeutic Classification: Antineoplastic and immunomodulating agents (ATC code L01).

Related Therapies: Other PDGFRA-targeted agents and broad-spectrum tyrosine kinase inhibitors used in GIST management, including agents targeting KIT mutations.

First Approval: United States (NDA 212608); European Union (27 November 2025, EMEA/H/C/005208).

Patent Status: Not yet disclosed in available facts.

United States (FDA): Avapritinib approved under NDA 212608; specific approval date not disclosed in available facts.

European Union (EMA): Avapritinib (AYVAKYT) approved on 27 November 2025 under EMA product number EMEA/H/C/005208. Marketing Authorization Holder: Blueprint Medicines (Netherlands) B.V.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

The drug has achieved regulatory approval in two major markets (US and EU), confirming clinical efficacy and safety validation. The EU approval date of 27 November 2025 represents the most recent disclosed regulatory milestone. Approval timelines and specific regulatory pathways (e.g., accelerated review, orphan drug designation) are not yet disclosed in available facts.

Strategic Implications: Blueprint Medicines' development of avapritinib reflects a precision oncology strategy targeting rare, molecularly-defined tumor subtypes. The completion of Phase 3 trials and regulatory approvals in the US and EU validate the clinical hypothesis that PDGFRA-specific inhibition provides therapeutic benefit in GIST. The company's focus on orphan oncology indications aligns with the rarity-driven pricing environment and reduced competitive pressure in niche markets.

Competitive Implications: Avapritinib's PDGFRA specificity differentiates it from broad-spectrum kinase inhibitors and multimodal oncology agents in the competitive landscape. The approval in major markets establishes Blueprint Medicines as a player in GIST therapeutics, though market penetration will depend on clinical evidence of superior efficacy or tolerability versus existing standards of care. The precision medicine positioning reduces direct competition with agents lacking PDGFRA specificity.

Future Catalysts: Key upcoming milestones include publication of Phase 3 trial data in peer-reviewed journals, real-world evidence generation post-approval, potential label expansions to additional GIST subtypes or earlier lines of therapy, and geographic expansion to additional regulatory markets (Japan, China). Biomarker-driven patient stratification and companion diagnostic development may enhance clinical utility and market adoption.

Expected Milestones: Specific dates for next regulatory or clinical milestones are not yet disclosed. Anticipated activities include post-marketing surveillance, health economics studies, and potential combination therapy investigations.